MedTrace Logo

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

NCT07527221 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-07-28

No results posted yet for this study

Summary

This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in healthy adult volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ZE74-0282-0001 or placebo

The participant will receive ZE74-0282-0001 or placebo

Sponsors & Collaborators

  • Eilean Therapeutics AU Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-16
Primary Completion
2026-11-30
Completion
2027-01-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07527221 on ClinicalTrials.gov